— JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years —
— JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain —Continue reading
Internationally acclaimed innovator to ‘reengineer the future of health’ in new role
Pending accreditation, ASU’s School of Medicine and Advanced Medical Engineering is expected to begin enrolling students later this year and open in fall 2026. Continue reading
Mayo Clinic is participating in the first in-human investigation of regenerative therapy for the treatment of drug-resistant epilepsy. The multicenter study will test the safety of implanting interneurons into the hippocampus in patients with the disease. Future studies are planned to investigate the potential for these cells to restore normal excitatory-inhibitory balance.Continue reading
The new center is seen as a worldwide bridge among scientists, researchers and physicians in their pursuit of new diagnostics and therapeutics to benefit patientsContinue reading
Funding expands manufacturing readiness for Valley fever vaccine. This follows Anivive’s $33MM NIAID contract for fungal vaccines
In total, Anivive has secured over $80MM in contracts and preordersContinue reading
Report shows ASU is a major economic engine driving the state through investments, spinoffs, research, taxes paid by alumni and more.Continue reading
Focuses genomic and proteomic lenses on three canine cancers
Continue reading
Experimental, three-drug chemotherapy regimen didn’t improve survival rates for patients, but treatment might still prove helpful for a small subset of patients.Continue reading
Financing Led by Evidity Health Capital Continue reading